Works matching AU Siebert, Nikolai

Results: 26

GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.

Published in:

Journal of Neuro-Oncology, 2020, v. 147, n. 3, p. 577, doi. 10.1007/s11060-020-03470-3

By:

Marx, Sascha;
Wilken, Fabian;
Wagner, Isabel;
Marx, Madlen;
Troschke-Meurer, Sascha;
Zumpe, Maxi;
Bien-Moeller, Sandra;
Weidemeier, Martin;
Baldauf, Joerg;
Fleck, Steffen K.;
Rauch, Bernhard H.;
Schroeder, Henry W. S.;
Lode, Holger;
Siebert, Nikolai

Publication type:

Article

Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

Published in:

2018

By:

Ceylan, Kiraz;
Jahns, Luciana J.;
Lode, Bjoern N.;
Ehlert, Karoline;
Kietz, Silke;
Troschke‐Meurer, Sascha;
Siebert, Nikolai;
Lode, Holger N.;
Troschke-Meurer, Sascha

Publication type:

journal article

Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.

Published in:

PLoS ONE, 2016, v. 11, n. 3, p. 1, doi. 10.1371/journal.pone.0150479

By:

Eger, Christin;
Siebert, Nikolai;
Seidel, Diana;
Zumpe, Maxi;
Jüttner, Madlen;
Brandt, Sven;
Müller, Hans-Peter;
Lode, Holger N.

Publication type:

Article

BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αβ CD8+ T cells.

Published in:

OncoImmunology, 2022, v. 11, n. 1, p. 1, doi. 10.1080/2162402X.2022.2148850

By:

Forkel, Hannes;
Grabarczyk, Piotr;
Depke, Maren;
Troschke-Meurer, Sascha;
Simm, Stefan;
Hammer, Elke;
Michalik, Stephan;
Hentschker, Christian;
Corleis, Björn;
Loyal, Lucie;
Zumpe, Maxi;
Siebert, Nikolai;
Dorhoi, Anca;
Thiel, Andreas;
Lode, Holger;
Völker, Uwe;
Schmidt, Christian A.

Publication type:

Article

Reduction of CD11b+ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD2 antibody ch14.18/CHO.

Published in:

OncoImmunology, 2020, v. 9, n. 1, p. 1, doi. 10.1080/2162402X.2020.1836768

By:

Siebert, Nikolai;
Zumpe, Maxi;
von Lojewski, Leon;
Troschke-Meurer, Sascha;
Marx, Madlen;
Lode, Holger N.

Publication type:

Article

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.

Published in:

OncoImmunology, 2019, v. 8, n. 12, p. 1, doi. 10.1080/2162402X.2019.1661194

By:

Troschke-Meurer, Sascha;
Siebert, Nikolai;
Marx, Madlen;
Zumpe, Maxi;
Ehlert, Karoline;
Mutschlechner, Oliver;
Loibner, Hans;
Ladenstein, Ruth;
Lode, Holger N.

Publication type:

Article

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD 2 antibody ch14.18/CHO.

Published in:

OncoImmunology, 2017, v. 6, n. 10, p. N.PAG, doi. 10.1080/2162402X.2017.1343775

By:

Siebert, Nikolai;
Zumpe, Maxi;
Jüttner, Madlen;
Troschke-Meurer, Sascha;
Lode, Holger N.

Publication type:

Article

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD 2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.

Published in:

OncoImmunology, 2016, v. 5, n. 11, p. N.PAG, doi. 10.1080/2162402X.2016.1235108

By:

Siebert, Nikolai;
Jensen, Christian;
Troschke-Meurer, Sascha;
Zumpe, Maxi;
Jüttner, Madlen;
Ehlert, Karoline;
Kietz, Silke;
Müller, Ina;
Lode, Holger N.

Publication type:

Article

Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma.

Published in:

Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 10, p. 2581, doi. 10.1007/s00432-021-03780-7

By:

Schriegel, Felix;
Taschner-Mandl, Sabine;
Bernkopf, Marie;
Grunwald, Uwe;
Siebert, Nikolai;
Ambros, Peter F.;
Ambros, Inge;
Lode, Holger N.;
Henze, Guenter;
Ehlert, Karoline

Publication type:

Article

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.

Published in:

Cancers, 2018, v. 10, n. 10, p. 387, doi. 10.3390/cancers10100387

By:

Siebert, Nikolai;
Troschke-Meurer, Sascha;
Marx, Madlen;
Zumpe, Maxi;
Ehlert, Karoline;
Gray, Juliet;
Garaventa, Alberto;
Manzitti, Carla;
Ash, Shifra;
Klingebiel, Thomas;
Beck, James;
Castel, Victoria;
Valteau-Couanet, Dominique;
Loibner, Hans;
Ladenstein, Ruth;
Lode, Holger N.

Publication type:

Article

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

Published in:

Cancer Immunology, Immunotherapy, 2015, v. 64, n. 5, p. 621, doi. 10.1007/s00262-015-1669-5

By:

Seidel, Diana;
Shibina, Anastasia;
Siebert, Nikolai;
Wels, Winfried;
Reynolds, C.;
Huebener, Nicole;
Lode, Holger

Publication type:

Article

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD-specific anti-neuroblastoma immune response.

Published in:

Cancer Immunology, Immunotherapy, 2013, v. 62, n. 6, p. 999, doi. 10.1007/s00262-013-1413-y

By:

Lode, Holger;
Schmidt, Manuela;
Seidel, Diana;
Huebener, Nicole;
Brackrock, Diana;
Bleeke, Matthias;
Reker, Daniel;
Brandt, Sven;
Mueller, Hans-Peter;
Helm, Christiane;
Siebert, Nikolai

Publication type:

Article

Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice.

Published in:

PLoS ONE, 2018, v. 13, n. 11, p. 1, doi. 10.1371/journal.pone.0207320

By:

Marx, Madlen;
Zumpe, Maxi;
Troschke-Meurer, Sascha;
Shah, Diana;
Lode, Holger N.;
Siebert, Nikolai

Publication type:

Article

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.

Published in:

British Journal of Cancer, 2023, v. 129, n. 11, p. 1780, doi. 10.1038/s41416-023-02457-x

By:

Lode, Holger N.;
Ehlert, Karoline;
Huber, Stephanie;
Troschke-Meurer, Sascha;
Siebert, Nikolai;
Zumpe, Maxi;
Loibner, Hans;
Ladenstein, Ruth

Publication type:

Article

Hepatocellular apoptosis is mediated by TNFα-dependent Fas/FasLigand cytotoxicity in a murine model of acute liver failure.

Published in:

Apoptosis, 2008, v. 13, n. 12, p. 1427, doi. 10.1007/s10495-008-0269-7

By:

Kuhla, Angela;
Eipel, Christian;
Siebert, Nikolai;
Abshagen, Kerstin;
Menger, Michael;
Vollmar, Brigitte

Publication type:

Article

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.

Published in:

Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.690467

By:

Seitz, Christian Martin;
Flaadt, Tim;
Mezger, Markus;
Lang, Anne-Marie;
Michaelis, Sebastian;
Katz, Marie;
Syring, Desireé;
Joechner, Alexander;
Rabsteyn, Armin;
Siebert, Nikolai;
Troschke-Meurer, Sascha;
Zumpe, Maxi;
Lode, Holger N.;
Yang, Sile F.;
Atar, Daniel;
Mast, Anna-Sophia;
Scheuermann, Sophia;
Heubach, Florian;
Handgretinger, Rupert;
Lang, Peter

Publication type:

Article

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.

Published in:

Cancers, 2023, v. 15, n. 13, p. 3364, doi. 10.3390/cancers15133364

By:

Lode, Holger N.;
Ladenstein, Ruth;
Troschke-Meurer, Sascha;
Struppe, Linda;
Siebert, Nikolai;
Zumpe, Maxi;
Ehlert, Karoline;
Huber, Stefanie;
Glogova, Evgenia;
Hundsdoerfer, Patrick;
Eggert, Angelika;
Zaniewska-Tekieli, Anna;
Balwierz, Walentyna;
Wieczorek, Aleksandra

Publication type:

Article

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.

Published in:

Cancers, 2023, v. 15, n. 13, p. 3317, doi. 10.3390/cancers15133317

By:

Siebert, Nikolai;
Zumpe, Maxi;
Schwencke, Christian Heinrich;
Biskupski, Simon;
Troschke-Meurer, Sascha;
Leopold, Justus;
Zikoridse, Alexander;
Lode, Holger N.

Publication type:

Article

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models.

Published in:

Cancers, 2023, v. 15, n. 3, p. 904, doi. 10.3390/cancers15030904

By:

Troschke-Meurer, Sascha;
Zumpe, Maxi;
Meißner, Lena;
Siebert, Nikolai;
Grabarczyk, Piotr;
Forkel, Hannes;
Maletzki, Claudia;
Bekeschus, Sander;
Lode, Holger N.

Publication type:

Article

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments.

Published in:

Cancers, 2022, v. 14, n. 23, p. 5802, doi. 10.3390/cancers14235802

By:

Klingel, Leah;
Siebert, Nikolai;
Troschke-Meurer, Sascha;
Zumpe, Maxi;
Ehlert, Karoline;
Huber, Stefanie;
Loibner, Hans;
Mutschlechner, Oliver;
Lode, Holger N.

Publication type:

Article

Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients.

Published in:

Cancers, 2022, v. 14, n. 23, p. 5751, doi. 10.3390/cancers14235751

By:

Marx, Sascha;
Wilken, Fabian;
Miebach, Lea;
Ispirjan, Mikael;
Kinnen, Frederik;
Paul, Sebastian;
Bien-Möller, Sandra;
Freund, Eric;
Baldauf, Jörg;
Fleck, Steffen;
Siebert, Nikolai;
Lode, Holger;
Stahl, Andreas;
Rauch, Bernhard H.;
Singer, Stephan;
Ritter, Christoph;
Schroeder, Henry W. S.;
Bekeschus, Sander

Publication type:

Article

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD 2 Antibody Dinutuximab Beta.

Published in:

Cancers, 2022, v. 14, n. 19, p. 4842, doi. 10.3390/cancers14194842

By:

Siebert, Nikolai;
Leopold, Justus;
Zumpe, Maxi;
Troschke-Meurer, Sascha;
Biskupski, Simon;
Zikoridse, Alexander;
Lode, Holger N.

Publication type:

Article

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody.

Published in:

PLoS ONE, 2014, v. 9, n. 9, p. 1, doi. 10.1371/journal.pone.0107692

By:

Siebert, Nikolai;
Seidel, Diana;
Eger, Christin;
Jüttner, Madlen;
Lode, Holger N.

Publication type:

Article

GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18.

Published in:

Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.839783

By:

Glienke, Wolfgang;
Dragon, Anna Christina;
Zimmermann, Katharina;
Martyniszyn-Eiben, Alexandra;
Mertens, Mira;
Abken, Hinrich;
Rossig, Claudia;
Altvater, Bianca;
Aleksandrova, Krasimira;
Arseniev, Lubomir;
Kloth, Christina;
Stamopoulou, Andriana;
Moritz, Thomas;
Lode, Holger N.;
Siebert, Nikolai;
Blasczyk, Rainer;
Goudeva, Lilia;
Schambach, Axel;
Köhl, Ulrike;
Eiz-Vesper, Britta

Publication type:

Article

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD 2 antibody ch14.18/CHO.

Published in:

mAbs (1942-0862), 2018, v. 10, n. 1, p. 55, doi. 10.1080/19420862.2017.1402997

By:

Mueller, Ina;
Ehlert, Karoline;
Endres, Stefanie;
Pill, Lena;
Siebert, Nikolai;
Kietz, Silke;
Brock, Penelope;
Garaventa, Alberto;
Valteau-Couanet, Dominique;
Janzek, Evelyne;
Hosten, Norbert;
Zinke, Andreas;
Barthlen, Winfried;
Varol, Emine;
Loibner, Hans;
Ladenstein, Ruth;
Lode, Holger N.

Publication type:

Article

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.

Published in:

mAbs (1942-0862), 2016, v. 8, n. 3, p. 604, doi. 10.1080/19420862.2015.1130196

By:

Siebert, Nikolai;
Eger, Christin;
Seidel, Diana;
Jüttner, Madlen;
Zumpe, Maxi;
Wegner, Danilo;
Kietz, Silke;
Ehlert, Karoline;
Veal, Gareth J.;
Siegmund, Werner;
Weiss, Michael;
Loibner, Hans;
Ladenstein, Ruth;
Lode, Holger N.

Publication type:

Article

Works matching AU Siebert, Nikolai

GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.

Inflammatory response and treatment tolerance of long-term infusion of the anti-GD<sub>2</sub> antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

Generation and Characterization of a Human/Mouse Chimeric GD<sub>2</sub>-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.

BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αβ CD8+ T cells.

Reduction of CD11b<sup>+</sup> myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD<sub>2</sub> antibody ch14.18/CHO.

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD 2 antibody ch14.18/CHO.

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD 2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.

Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma.

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD-specific anti-neuroblastoma immune response.

Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice.

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.

Hepatocellular apoptosis is mediated by TNFα-dependent Fas/FasLigand cytotoxicity in a murine model of acute liver failure.

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models.

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments.

Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients.

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD 2 Antibody Dinutuximab Beta.

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD<sub>2</sub> Antibody.

GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD<sub>2</sub> and Releasing Inducible IL-18.

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD 2 antibody ch14.18/CHO.

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.